Form 4: Community Health Systems Regional President Chad A. Campbell Reports Changes in Beneficial Ownership
SEC Form 4
Chad A. Campbell, Regional President of Community Health Systems, reports transactions involving common stock and derivative securities, including the vesting of performance-based restricted shares and stock options.
Summary
- On March 1, 2024, Chad A. Campbell, Regional President of Community Health Systems, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- The transactions included the vesting of 15,000 performance-based restricted shares, the acquisition of 25,000 shares of common stock, and the disposition of 14,431 shares to cover tax obligations.
- Campbell also acquired 50,000 performance-based restricted shares tied to the company's performance between 2024 and 2026, and 25,000 stock options.
- Following these transactions, Campbell directly owns 115,287 shares of Community Health Systems common stock, 50,000 performance based restricted shares related to the 2024-2026 performance period, 50,000 performance based restricted shares related to the 2022-2024 performance period, 50,000 performance based restricted shares related to the 2023-2025 performance period, and various stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to executive compensation. The vesting of performance-based shares is a positive signal, but the sale of shares for tax obligations is a minor negative.
Positives
- The vesting of performance-based restricted shares indicates that certain performance objectives were met between 2021 and 2023.
- The acquisition of additional shares and stock options demonstrates Campbell's continued investment in the company.
Negatives
- The disposition of 14,431 shares to cover tax obligations, while a normal occurrence, slightly reduces Campbell's holdings.
Risks
- The vesting of future performance-based restricted shares is contingent on the company's ability to meet specific performance objectives related to EBITDA and revenue growth.
- The value of stock options is dependent on the future performance of the company's stock price.
Future Outlook
Future vesting of performance-based restricted shares is dependent on the company's performance against pre-determined objectives related to Cumulative Consolidated Adjusted EBITDA Growth and Cumulative Same-Store Net Revenue Growth between 2024 and 2026.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages in the healthcare industry often include a mix of salary, stock options, and performance-based restricted stock.
- The specific performance metrics used for vesting restricted stock, such as EBITDA and revenue growth, are common in the healthcare sector.
- Comparing the vesting schedules and performance targets to those of peer companies like HCA Healthcare or Tenet Healthcare would provide further context.
Stakeholder Impact
- Shareholders may view the vesting of performance-based restricted shares as a positive sign that management is incentivized to achieve company goals.
- Employees may be indirectly affected by the company's performance against the targets, as it could influence overall compensation and job security.
Next Steps
- Monitor future Form 4 filings by Campbell and other company insiders for further insights into their investment activity.
- Track the company's performance against the EBITDA and revenue growth targets associated with the performance-based restricted shares.
Key Dates
| Date | Description |
|---|---|
| 03/01/2021 | Date performance-based restricted shares were originally reported. |
| 03/02/2021 | Date performance-based restricted shares were originally reported by the Reporting Person. |
| 03/01/2021 | Date of stock options grant with exercise price $4.93 and expiration 02/28/2030. |
| 03/01/2022 | Date of stock options grant with exercise price $8.81 and expiration 02/28/2031. |
| 03/01/2023 | Date of stock options grant with exercise price $10.18 and expiration 02/29/2032. |
| 09/15/2023 | Date of Power of Attorney execution. |
| 03/01/2024 | Date of transactions reported on Form 4, including vesting of performance-based restricted shares, acquisition of common stock, and disposition of shares for tax obligations. |
| 03/01/2024 | Date of stock options grant with exercise price $2.87, vesting in increments until 03/01/2025 and expiring on 02/28/2034. |
| 03/01/2025 | First vesting date for stock options granted on 03/01/2024. |
| 02/28/2030 | Expiration date for stock options granted on 03/01/2021. |
| 02/28/2031 | Expiration date for stock options granted on 03/01/2022. |
| 02/29/2032 | Expiration date for stock options granted on 03/01/2023. |
| 02/28/2033 | Expiration date for stock options granted on 03/01/2024. |
| 02/28/2034 | Expiration date for stock options granted on 03/01/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.